💊FDA PHARMA today 💊FDA PHARMA to Tuesday December 19th, 2017By Tokio X'press offices, FDA, Pharmaceutical ONO
💊Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc 💊 Tuesday December 12th, 2017By Tokio X'press Pharmaceutical ONO
💊Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Saturday November 11th, 2017By Tokio X'press Pharmaceutical ONO
💊European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma Wednesday November 1st, 2017By Tokio X'press Pharmaceutical ONO
💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors 20171012 Friday October 13th, 2017By Tokio X'press JPN, Pharmaceutical ONO
